HomeProductsBuilding BlocksHeterocyclic ScaffoldsPyridinesLanicemine
Chemical structure of CAS 153322-05-5

Lanicemine

CAS No.153322-05-5
MDL No.MFCD00924222
MFC13H14N2
MW198.26
InChI KeyFWUQWDCOOWEXRY-ZDUSSCGKSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.153322-05-5
Product NameLanicemine

Biological Targets

GRIN1·GRIN2A·GRIN2B·GRIN2D·GRIN3B·

Associated Conditions

major depressive disorder·depressive disorder
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Nature reviews. Drug discovery • Vol. 13, Issue 6 • 2014
PMID: 24833294DOI: 10.1038/nrd4309

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.

Biological psychiatry • Vol. 74, Issue 4 • 2013
PMID: 23206319PMC: PMC3594049DOI: 10.1016/j.biopsych.2012.10.019

Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block.

The Journal of pharmacology and experimental therapeutics • Vol. 297, Issue 3 • 2001
PMID: 11356910

NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology.

The Journal of pharmacology and experimental therapeutics • Vol. 280, Issue 2 • 1997
PMID: 9023271

Documentation

Similar Products